Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Dec;86(24):10054–10058. doi: 10.1073/pnas.86.24.10054

Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.

M Barel 1, A Fiandino 1, F Lyamani 1, R Frade 1
PMCID: PMC298642  PMID: 2557614

Abstract

Epstein-Barr virus and the C3d fragment of the third component of complement are specific extracellular ligands for complement receptor type 2 (CR2). However, intracellular proteins that react specifically with CR2 and are involved in post-membrane signals remain unknown. We recently prepared polyclonal anti-idiotypic anti-CR2 antibodies (Ab2) by using the highly purified CR2 molecule as original immunogen. We showed that Ab2 contained anti-idiotypic specificities that mimicked extracellular domains of CR2 and detected two distinct binding sites on CR2 for its specific extracellular ligands, Epstein-Barr virus and C3d. We postulated that Ab2 might also contain specificities that could mimic intracellular domains of CR2. Here we report that Ab2, which did not react with Raji B-lymphoma cell surface components, detected specifically, among all components solubilized from Raji cell membranes, a single intracellular membrane protein of apparent molecular mass of 53 kDa. This protein was identified as the p53 cellular antioncogene-encoded membrane phosphoprotein by analyzing its antigenic properties with Pab1801, a monoclonal anti-p53 antibody, and by comparing its biochemical properties with those of p53. Additionally, solubilized and purified CR2 bound to solubilized p53 immobilized on Pab1801-Sepharose. p53, like CR2, was localized only in purified plasma membranes and nuclei of Raji cells. These data suggest strongly that p53, a cellular antioncogene-encoded phosphoprotein, reacted specifically with CR2 in Raji membranes. This interaction may represent one of the important steps through which CR2 could be involved in human B-lymphocyte proliferation and transformation.

Full text

PDF
10054

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banks L., Matlashewski G., Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem. 1986 Sep 15;159(3):529–534. doi: 10.1111/j.1432-1033.1986.tb09919.x. [DOI] [PubMed] [Google Scholar]
  2. Barel M., Charriaut C., Frade R. Isolation and characterization of a C3b receptor-like molecule from membranes of a human B lymphoblastoid cell line (Raji). FEBS Lett. 1981 Dec 21;136(1):111–114. doi: 10.1016/0014-5793(81)81225-2. [DOI] [PubMed] [Google Scholar]
  3. Barel M., Fiandino A., Delcayre A. X., Lyamani F., Frade R. Monoclonal and anti-idiotypic anti-EBV/C3d receptor antibodies detect two binding sites, one for EBV and one for C3d on glycoprotein 140, the EBV/C3dR, expressed on human B lymphocytes. J Immunol. 1988 Sep 1;141(5):1590–1595. [PubMed] [Google Scholar]
  4. Barel M., Vazquez A., Charriaut C., Aufredou M. T., Galanaud P., Frade R. gp 140, the C3d/EBV receptor (CR2), is phosphorylated upon in vitro activation of human peripheral B lymphocytes. FEBS Lett. 1986 Mar 3;197(1-2):353–356. doi: 10.1016/0014-5793(86)80356-8. [DOI] [PubMed] [Google Scholar]
  5. Bijsterbosch M. K., Meade C. J., Turner G. A., Klaus G. G. B lymphocyte receptors and polyphosphoinositide degradation. Cell. 1985 Jul;41(3):999–1006. doi: 10.1016/s0092-8674(85)80080-5. [DOI] [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  7. Carter R. H., Spycher M. O., Ng Y. C., Hoffman R., Fearon D. T. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol. 1988 Jul 15;141(2):457–463. [PubMed] [Google Scholar]
  8. Changelian P. S., Fearon D. T. Tissue-specific phosphorylation of complement receptors CR1 and CR2. J Exp Med. 1986 Jan 1;163(1):101–115. doi: 10.1084/jem.163.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Coggeshall K. M., Cambier J. C. B cell activation. VIII. Membrane immunoglobulins transduce signals via activation of phosphatidylinositol hydrolysis. J Immunol. 1984 Dec;133(6):3382–3386. [PubMed] [Google Scholar]
  10. Crawford L. V., Pim D. C., Gurney E. G., Goodfellow P., Taylor-Papadimitriou J. Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. Proc Natl Acad Sci U S A. 1981 Jan;78(1):41–45. doi: 10.1073/pnas.78.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Delcayre A. X., Fiandino A., Barel M., Frade R. gp140, the EBV/C3d receptor (CR2) of human B lymphocytes, is involved in cell-free phosphorylation of p120, a nuclear ribonucleoprotein. Eur J Immunol. 1987 Dec;17(12):1827–1833. doi: 10.1002/eji.1830171223. [DOI] [PubMed] [Google Scholar]
  12. Delcayre A. X., Fiandino A., Lyamani F., Barel M., Frade R. Enhancement of Epstein-Barr virus/C3d receptor (EBV/C3dR or CR2) and nuclear p120 ribonucleoprotein phosphorylation by specific EBV/C3dR ligands in subcellular fractions of the human B lymphoma cell line, Raji. Biochem Biophys Res Commun. 1989 Mar 31;159(3):1213–1220. doi: 10.1016/0006-291x(89)92239-0. [DOI] [PubMed] [Google Scholar]
  13. Deppert W., Haug M. Evidence for free and metabolically stable p53 protein in nuclear subfractions of simian virus 40-transformed cells. Mol Cell Biol. 1986 Jun;6(6):2233–2240. doi: 10.1128/mcb.6.6.2233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Frade R., Barel M., Ehlin-Henriksson B., Klein G. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1490–1493. doi: 10.1073/pnas.82.5.1490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Frade R., Barel M., Krikorian L., Charriaut C. Analysis of gp 140, a C3b-binding membrane component present on Raji cells: a comparison with factor H. Eur J Immunol. 1984 Jun;14(6):542–548. doi: 10.1002/eji.1830140611. [DOI] [PubMed] [Google Scholar]
  16. Frade R., Crevon M. C., Barel M., Vazquez A., Krikorian L., Charriaut C., Galanaud P. Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule. Eur J Immunol. 1985 Jan;15(1):73–76. doi: 10.1002/eji.1830150114. [DOI] [PubMed] [Google Scholar]
  17. Frade R., Myones B. L., Barel M., Krikorian L., Charriaut C., Ross G. D. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4). Eur J Immunol. 1985 Dec;15(12):1192–1197. doi: 10.1002/eji.1830151210. [DOI] [PubMed] [Google Scholar]
  18. Frade R. Structure and functions of gp 140, the C3d/EBV receptor (CR2) of human B lymphocytes. Mol Immunol. 1986 Nov;23(11):1249–1253. doi: 10.1016/0161-5890(86)90159-8. [DOI] [PubMed] [Google Scholar]
  19. Fujisaku A., Harley J. B., Frank M. B., Gruner B. A., Frazier B., Holers V. M. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J Biol Chem. 1989 Feb 5;264(4):2118–2125. [PubMed] [Google Scholar]
  20. Green M. R. When the products of oncogenes and anti-oncogenes meet. Cell. 1989 Jan 13;56(1):1–3. doi: 10.1016/0092-8674(89)90975-6. [DOI] [PubMed] [Google Scholar]
  21. Hatzfeld J., Charriaut-Marlangue C., Levesque J. P., Barel M., Stancou R., Krikorian L., Hatzfeld A., Frade R. Le C3 stimule la prolifération des cellules humaines pré-B de la lignée Raji. Ann Inst Pasteur Immunol. 1987 May-Jun;138(3):451–455. doi: 10.1016/s0769-2625(87)80055-7. [DOI] [PubMed] [Google Scholar]
  22. Hinds P., Finlay C., Levine A. J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol. 1989 Feb;63(2):739–746. doi: 10.1128/jvi.63.2.739-746.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Jay G., Khoury G., DeLeo A. B., Dippold W. G., Old L. J. p53 transformation-related protein: detection of an associated phosphotransferase activity. Proc Natl Acad Sci U S A. 1981 May;78(5):2932–2936. doi: 10.1073/pnas.78.5.2932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jörnvall H., Luka J., Klein G., Appella E. A 53-kilodalton protein common to chemically and virally transformed cells shows extensive sequence similarities between species. Proc Natl Acad Sci U S A. 1982 Jan;79(2):287–291. doi: 10.1073/pnas.79.2.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  26. Lambris J. D., Ganu V. S., Hirani S., Müller-Eberhard H. J. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4235–4239. doi: 10.1073/pnas.82.12.4235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lane D. P., Crawford L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979 Mar 15;278(5701):261–263. doi: 10.1038/278261a0. [DOI] [PubMed] [Google Scholar]
  28. Luka J., Jörnvall H., Klein G. Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit. J Virol. 1980 Sep;35(3):592–602. doi: 10.1128/jvi.35.3.592-602.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Masucci M. G., Szigeti R., Ernberg I., Hu C. P., Torsteinsdottir S., Frade R., Klein E. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction. Eur J Immunol. 1987 Jun;17(6):815–820. doi: 10.1002/eji.1830170613. [DOI] [PubMed] [Google Scholar]
  30. McKeel D. W., Jarett L. Preparation and characterization of a plasma membrane fraction from isolated fat cells. J Cell Biol. 1970 Feb;44(2):417–432. doi: 10.1083/jcb.44.2.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Melchers F., Erdei A., Schulz T., Dierich M. P. Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature. 1985 Sep 19;317(6034):264–267. doi: 10.1038/317264a0. [DOI] [PubMed] [Google Scholar]
  32. Moore M. D., Cooper N. R., Tack B. F., Nemerow G. R. Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9194–9198. doi: 10.1073/pnas.84.24.9194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nadler L. M., Stashenko P., Hardy R., van Agthoven A., Terhorst C., Schlossman S. F. Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol. 1981 May;126(5):1941–1947. [PubMed] [Google Scholar]
  34. Nemerow G. R., McNaughton M. E., Cooper N. R. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol. 1985 Nov;135(5):3068–3073. [PubMed] [Google Scholar]
  35. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 1984 Apr 19;308(5961):693–698. doi: 10.1038/308693a0. [DOI] [PubMed] [Google Scholar]
  36. Pinhasi-Kimhi O., Michalovitz D., Ben-Zeev A., Oren M. Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature. 1986 Mar 13;320(6058):182–184. doi: 10.1038/320182a0. [DOI] [PubMed] [Google Scholar]
  37. Rodriguez de Córdoba S., Rubinstein P., Ferreira A. High resolution isoelectric focusing of immunoprecipitated proteins under denaturing conditions. A simple analytical method applied to the study of complement component polymorphisms. J Immunol Methods. 1984 Apr 27;69(2):165–172. doi: 10.1016/0022-1759(84)90314-4. [DOI] [PubMed] [Google Scholar]
  38. Rotter V., Abutbul H., Ben-Ze'ev A. P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. EMBO J. 1983;2(7):1041–1047. doi: 10.1002/j.1460-2075.1983.tb01543.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Rotter V., Wolf D. Biological and molecular analysis of p53 cellular-encoded tumor antigen. Adv Cancer Res. 1985;43:113–141. doi: 10.1016/s0065-230x(08)60944-6. [DOI] [PubMed] [Google Scholar]
  40. Sarnow P., Ho Y. S., Williams J., Levine A. J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 1982 Feb;28(2):387–394. doi: 10.1016/0092-8674(82)90356-7. [DOI] [PubMed] [Google Scholar]
  41. Tanner J., Whang Y., Sample J., Sears A., Kieff E. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J Virol. 1988 Dec;62(12):4452–4464. doi: 10.1128/jvi.62.12.4452-4464.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Weis J. J., Toothaker L. E., Smith J. A., Weis J. H., Fearon D. T. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med. 1988 Mar 1;167(3):1047–1066. doi: 10.1084/jem.167.3.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES